Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

被引:497
|
作者
Ogitani, Yusuke [1 ]
Hagihara, Katsunobu [2 ]
Oitate, Masataka [2 ]
Naito, Hiroyuki [3 ]
Agatsuma, Toshinori [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词
Antibody-drug conjugate; bystander killing; HER2; T-DM; topoisomerase I inhibitor; BRENTUXIMAB VEDOTIN; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; CATHEPSIN-B; EXPRESSION; LYMPHOMA; THERAPY; PHASE-3; SAFETY;
D O I
10.1111/cas.12966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文
共 50 条
  • [31] The human epidermal growth factor receptor 2 (HER2)
    Tafe, Laura J.
    Tsongalis, Gregory J.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2012, 50 (01) : 23 - 30
  • [32] Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab
    Ye, Hua
    Chai, Xuyu
    Wang, Xiaoyu
    Zheng, Qi
    Zheng, Dingcheng
    Wu, Feng
    Zheng, Cheng
    Chen, Ping
    ONCOLOGY LETTERS, 2018, 15 (04) : 4143 - 4150
  • [33] Development of an In Vitro Potency Assay System for Quality Control of Anti-Human Epidermal Growth Factor Receptor 2 Antibody Admixtures
    Hu, P. Lv Lide
    Yeh, J. Y.
    Gao, X.
    Liu, D.
    Wang, G.
    Liu, Y.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 83 (02) : 293 - 305
  • [34] Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
    Asazuma, Kazuki
    Shimomura, Akihiko
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (18) : 2066 - +
  • [35] Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer
    Teramoto, T
    Onda, M
    Tokunaga, A
    Asano, G
    CANCER, 1996, 77 (08) : 1639 - 1645
  • [36] The Association of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 with Prognosis of Colorectal Cancer under FOLFOX Chemotherapy
    Qian, H.
    Huang, Wenzhi
    Zhang, Y.
    Cheng, Xiaofei
    Zhong, C.
    Tian, F.
    Chu, Ziang
    Zhou, T.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 : 25 - 30
  • [37] Current Status of Anti-Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
    Chung, Alice
    Cui, Xiaojiang
    Audeh, William
    Giuliano, Armando
    CLINICAL BREAST CANCER, 2013, 13 (04) : 223 - 232
  • [38] New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer
    Britten, Karissa
    McAndrew, Nicholas
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2024, 36 (01) : 34 - 39
  • [39] A narrative review of human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates in the treatment of breast cancer
    Li, Qun
    Guo, Ye
    Lin, Fengjuan
    Li, Lingjun
    Ge, Xiaoxiao
    Zhao, Wei
    Li, Jin
    TRANSLATIONAL BREAST CANCER RESEARCH, 2021, 2
  • [40] A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors
    Xu, YM
    Wang, LF
    Jia, LT
    Qiu, XC
    Zhao, J
    Yu, CJ
    Zhang, R
    Zhu, F
    Wang, CJ
    Jin, BQ
    Chen, SY
    Yang, AG
    JOURNAL OF IMMUNOLOGY, 2004, 173 (01): : 61 - 67